Physician profile
Tamara Till
NPI 1619504248
$799.03
in general payments reported to CMS, 2019-2025
16 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $271 · 2022: $162 · 2023: $45.75 · 2024: $189 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $366.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $149.46 | 2021-2024 | Mounjaro, Zepbound |
| Zealand Pharma US, INC. | $103.33 | 2021-2022 | |
| Ascensia Diabetes Care US INC. | $88.40 | 2024-2025 | |
| Corcept Therapeutics | $79.31 | 2021-2025 | Korlym |
| Revance Therapeutics, INC. | $77.05 | 2024-2025 | Daxxify |
| Novo Nordisk INC | $69.80 | 2021-2024 | Wegovy, Rybelsus, Ozempic |
| Insulet Corporation | $44.73 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.76 | 2021 | |
| Amarin Pharma, INC. | $28.98 | 2021 | |
| Dexcom, INC. | $22.89 | 2024 | Dexcom G6 Transmitter |
| Genentech USA, INC. | $21.98 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $21.24 | 2022 | |
| Idorsia Pharmaceuticals US INC | $17.43 | 2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $14.90 | 2021 | |
| Abbvie INC. | $14.51 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $13.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Till listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.